Data-Driven Solutions for Neurodegenerative Diseases at Your Fingertips.

Digital Analytics Platform

We know patients aren’t diagnosed soon enough, they don’t know how the disease is progressing.

Artificial Intelligence

nQ Medical’s artificial intelligence-powered computational biomarker yields powerful insights. We believe that the way our fingers interact with computers can reveal the presence of certain neuromotor and neurocognition diseases like Parkinson’s, Alzheimer’s, ALS, and Multiple Sclerosis.

Proven Through Trials

The potential of our technology has been shown in clinical research at MIT, backed by the Michael J. Fox Foundation. We also have ongoing studies with the Cleveland Clinic and Massachusetts General Hospital to explore additional diseases.

Real World Data

The fine control of typing and touch screen kinematics, as well as the frequent use of personal devices like smart phones brings real world data to clinicians.

Challenge Met By Machine Learning

nQ uses machine learning to evaluate information obtained from the daily use of mechanical and touchscreen devices. Four clinical studies have demonstrated our ability to detect the pathological signs of neurological disease sooner than the tools we have today.

Beyond the potential for early detection of symptoms, our AI technology supports clinical trials by improving accuracy and efficiency in recruitment, 24/7, passive monitoring of disease progression from home, and measuring the impact of therapy on outcomes at a far more granular level than current gold standards.

What’s more, our platform provides unified data management across the entire lifecycle, from clinical trials to clinician dashboards, and from patient engagement to population health.

Key Uses of nQ’s Patented AI Technology

Recruitment and Support for Clinical Trials

nQ addresses the real challenges faced by clinical trials head on. Specifically, it helps with:

  • Remote, online recruitment of study participants by improving patient targeting and screening, thereby shrinking recruitment time.
  • Dependence on in-clinic observation is reduced by relying on at-home, unbiased real-world data.
  • Offers the potential to shape clinical trial design for neurodegenerative diseases with the earliest measure of therapeutic impact, thanks to passive, continuous monitoring of patients.

Exploratory Development of Future Applications to Measure Disease Progression

Future clinical applications in development include:

  • A mobile app used to monitor patient care remotely under the guidance of a healthcare professional in conjunction with other prescribed therapy.
  • A digital health device that supports clinical titration decisions, and a tool for patient engagement and adherence as well as caregiver observation.

What Specialists Think

In a recent survey1 of 2,305 movement disorder specialists, 95% of respondents indicated that the ability to monitor patients remotely is extremely valuable, very valuable or valuable.

Of current methods for the detection and monitoring of Parkinson’s Disease that are most in need of improvement, they single out:

  • The specificity and sensitivity of collected data for critical decision making (76%)
  • The lack of access to real-world, at home, patient data (56%)
  • The subjective nature of data collecting (55%)

Furthermore, specialists feel that the availability of remote monitoring and disease progression data, like nQ provides, could potentially positively impact patient care by:

  • Helping more accurately titrate medication (72%)
  • Providing useful data to support treatment decisions (71%)
  • Encouraging patients to become more involved in therapy (63%)
  • Improving patient adherence to medication (53%)
  • Assisting patients and caregivers better understand and manage the disease (50%)

The specialists have spoken, and we are on the same page.

1. Areas of improvement in tools currently available for early detection and disease monitoring of Parkinson’s. US Movement Disorder Specialist Survey. SERMO. February 19, 2019.

Our Clinical Partners

Asset 1

Recognized AI Solution

nQ Medical is pleased to be named a Top AI Start-Up by the PRISME Forum in 2017. Awards and accolades don’t drive us, but it’s nice to be recognized. Read the Business Insider article here.

Screen Shot 2019-03-21 at 12.22.22 PM

Breakthrough Innovation in Clinical Trials

nQ Medical is pleased to be honored with the D4 INNOVATION AWARD recognizing the most innovative breakthrough technology affecting data-driven drug development. Read the Frontline Genomics article here

Top eClinical Trial Solution
Provider of 2019

nQ Medical is please to be recognized by a distinguished selection panel of CEOs,
CIOs, VCs, Industry Analysts, and PharmaTech Outlook’s Editorial Board as one of the Top 10 eClinical Trial solution providers in 2019.

Our Leadership Team

  • R. A. Bavasso

    Founder & CEO

  • Mark Pascarella

    Founder & Executive Chairman

  • Teresa Arroyo Gallego, PhD

    Chief Data Scientist

  • Ijah Mondesire-Crump, MD

    Director, Clinical Research

  • Steven Han

    VP Engineering

  • Rahul Mahajan , MD

    Chief Medical Officer

Our Board of Advisors

  • John Baldoni, PhD

    SVP, R&D, GSK

  • Naomi Fried, PhD

    CEO, Health Innovation Strategies

  • David Kreutter, PhD

    Pfizer, Kreutter Life Sciences LLC

  • Maulik Majmudar, MD

    Chief Medical Officer, Health & Wellness, Amazon

  • Zoltan Mari, MD

    Chief, Movement Disorder Program, The Cleveland Clinic, Lou Ruvo Center for Brain Health

  • David Lee Scher, MD

    Cardiologist, Digital Health Consultant

Peer Reviewed Clinical Publications

Movement Disorders, 2019

Recent advances in technology are opening new opportunities to remotely evaluate motor features in people with Parkinson’s. This study showed that using nQ to monitor typing, a habitual behavior facilitated by the nigrostriatal dopaminergic pathway, could allow for objectively and non-obtrusively monitoring Parkinsonian features and response to medication in an at‐home setting.  Read the paper here.

Journal of Medical Internet Research, 2018

This publication is on the value of nQ as a remote monitoring tool for Parkinson’s. The paper compares nQ’s performance in-clinic and at-home and showed that it provides similar quality measurements as a traditional in-clinic evaluation. Read the paper here.

IEEE Transactions on Biomedical Engineering, 2017

In this study nQ presented our first result from the analysis of data gathered using smartphones. We showed that we can accurately discriminate an early PD population with mild Parkinsonian signs from a healthy control group by comparing the typing patterns from their interaction with touchscreen keyboards. Read the paper here.

Scientific Reports, 2016

In nQ’s first study focused on Parkinson’s Disease, we showed data indicating that the routine interaction with computer keyboards can be used to detect motor signs in the early stages of Parkinson’s. We presented a solution that relies on keystroke data from daily use of personal computers and converts it into a PD motor index. Read the paper here.

Scientific Reports, 2015

In this proof of concept study, nQ demonstrated that daily interaction with a computer keyboard can be employed as means to observe and potentially quantify psychomotor impairment. This initial work in sleep inertia demonstrates that clinically relevant motor function changes can be measured by timing key press/release events from a typing routine on a physical keyboard, irrespective of the language or the typed text. Read the paper here.

Get In Touch

Want to learn more about nQ Medical? Drop us a note and let us show you how we can help.

nQ Medical

245 Main Street
Cambridge, MA
02142

NQ Medical’s Software is not yet cleared by FDA. Any depictions of the technology are intended to be conceptual and illustrative and are not intended to convey exact representations of anatomy, physiology, structure, positioning, or performance of the technology.

© 2019 nQ Medical. All rights reserved.